Dr. Nina Bhardwaj is a professor of medicine, hematology, and medical oncology, and a professor of urology at the Icahn School of Medicine at Mount Sinai. She is currently one of the two study chairs of the clinical trial “A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers” (NCT02643303).
This study examines combinations of two checkpoint immunotherapies, plus an immune-stimulating adjuvant, in a wide variety of patients diagnosed with breast cancer, sarcoma, head and neck cancer, lymphoma, melanoma, bladder cancer, kidney cancer, prostate cancer, among other types of cancer. One checkpoint inhibitor, durvalumab (Imfinzi™), blocks the PD-L1 pathway, whereas the other, tremelimumab, blocks the CTLA-4 pathway. The adjuvant, poly ICLC, promotes an immune system response similar to that of vaccines.
Additional investigators working on this trial include:
- Craig L. Slingluff Jr., M.D. (University of Virginia Health System)
- Michael Lowe, M.D. (Emory University Hospital )
- Igor Puzanov, M.D. (Roswell Park Cancer Institute)
- Keisuke Shirai, M.D. (Dartmouth-Hitchock Medical Center)
- Megan Kruse, M.D. (Cleveland Clinic)
- Danae Hamouda, M.D. (University of Toledo)
Projects and Grants
Analysis of immune responses induced by in situ, autologous therapeutic vaccination against solid cancers with intratumoral hiltonol (Poly-ICLC).
Icahn School of Medicine at Mount Sinai | Melanoma, Sarcoma | 2016
A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers (NCT02643303)
Icahn School of Medicine at Mount Sinai | All Cancers | 2015
The mutation-derived tumor antigen landscape of advanced bladder cancer: A platform to optimize cancer immunotherapy
Icahn School of Medicine at Mount Sinai | Bladder Cancer | 2015